Serum microRNAs explain discordance of non-alcoholic fatty liver disease in monozygotic and dizygotic twins: A prospective study

Gut

Volumn 65, Issue 9, 2016, Pages 1546-1554

  Zarrinpar, Amir ^a,b   Gupta, Shakti ^c   Maurya, Mano R ^c   Subramaniam, Shankar ^a,c   Loomba, Rohit ^a,b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

fatty liver; genetics; liver; Nonalcoholic steatohepatitis; obesity

Indexed keywords

MICRORNA; MICRORNA 30C; MICRORNA 331 3P; UNCLASSIFIED DRUG; MIRN30 MICRORNA, HUMAN; MIRN331 MICRORNA, HUMAN;

ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DIZYGOTIC TWINS; FAT CONTENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOZYGOTIC TWINS; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNITED STATES; BLOOD; CALIFORNIA; DIAGNOSTIC IMAGING; GENE EXPRESSION PROFILING; GENETIC EPIGENESIS; GENETICS; LIVER; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; PROCEDURES; TWINS;

CALIFORNIA; CROSS-SECTIONAL STUDIES; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION PROFILING; HUMANS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MICRORNAS; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; PROSPECTIVE STUDIES; TWINS, DIZYGOTIC; TWINS, MONOZYGOTIC;

EID: 84931321456     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-309456     Document Type: Article

References (49)

1. Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34:274-85.
2. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-7.
3. Charlton MR, Burns JM, Pedersen RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141:1249-53.
4. Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010;51:1820-32.
5. Brouwers MC, Cantor RM, Kono N, et al. Heritability and genetic loci of fatty liver in familial combined hyperlipidemia. J Lipid Res 2006;47:2799-807.
6. Schwimmer JB, Celedon MA, Lavine JE, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology 2009;136:1585-92.
7. Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol 2013;10:542-52.
8. Sayed D, Abdellatif M. MicroRNAs in development and disease. Physiol Rev 2011;91:827-87.
9. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
10. Takahashi K, Yan I, Wen HJ, et al. microRNAs in liver disease: from diagnostics to therapeutics. Clin Biochem 2013;46:946-52.
11. Kerr TA, Korenblat KM, Davidson NO. MicroRNAs and liver disease. Transl Res 2011;157:241-52.
12. Wang XW, Heegaard NH, Orum H. MicroRNAs in liver disease. Gastroenterology 2012;142:1431-43.
13. Rottiers V, Naar AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012;13:239-50.
14. Cermelli S, Ruggieri A, Marrero JA, et al. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS ONE 2011;6:e23937.
15. Celikbilek M, Baskol M, Taheri S, et al. Circulating microRNAs in patients with non-alcoholic fatty liver disease. World J Hepatol 2014;6:613-20.
16. Pirola CJ, Fernandez Gianotti T, Castano GO, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 2015;64:800-12.
17. van Dongen J, Slagboom PE, Draisma HH, et al. The continuing value of twin studies in the omics era. Nat Rev Genet 2012;13:640-53.
18. Li YY. Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. World J Gastroenterol 2012;18:6546-51.
19. Pirola CJ, Gianotti TF, Burgueno AL, et al. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 2013;62:1356-63.
20. Boyd NF, Dite GS, Stone J, et al. Heritability of mammographic density, a risk factor for breast cancer. N Engl J Med 2002;347:886-94.
21. Noureddin M, Lam J, Peterson MR, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology 2013;58:1930-40.
22. Le TA, Chen J, Changchien C, et al. Effect of colesevelam on liver fat quantified by magnetic resonance in nonalcoholic steatohepatitis: a randomized controlled trial. Hepatology 2012;56:922-32.
23. Rinella ME, Loomba R, Caldwell SH, et al. Controversies in the diagnosis and management of NAFLD and NASH. Gastroenterol Hepatol (N Y) 2014;10:219-27.
24. Reeder SB, Cruite I, Hamilton G, et al. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging 2011;34:729-49.
25. Reeder SB. Emerging quantitative magnetic resonance imaging biomarkers of hepatic steatosis. Hepatology 2013;58:1877-80.
26. Castera L, Vilgrain V, Angulo P. Noninvasive evaluation of NAFLD. Nat Rev Gastroenterol Hepatol 2013;10:666-75.
27. Permutt Z, Le TA, Peterson MR, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease -MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther 2012;36:22-9.
28. Dweep H, Sticht C, Pandey P, et al. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Inform 2011;44:839-47.
29. Tilg H, Moschen AR. IL-1 cytokine family members and NAFLD: neglected in metabolic liver inflammation. J Hepatol 2011;55:960-2.
30. Gorden DL, Myers DS, Ivanova PT, et al. Biomarkers of NAFLD progression: a lipidomics approach to an epidemic. J Lipid Res 2015;56:722-36.
31. Loomba R, Rao F, Zhang L, et al. Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. Gastroenterology 2010;139:836-45, 45 e1.
32. Sarachana T, Zhou R, Chen G, et al. Investigation of post-transcriptional gene regulatory networks associated with autism spectrum disorders by microRNA expression profiling of lymphoblastoid cell lines. Genome Med 2010;2:23.
33. Te JL, Dozmorov IM, Guthridge JM, et al. Identification of unique microRNA signature associated with lupus nephritis. PLoS ONE 2010;5:e10344.
34. Bell JT, Spector TD. A twin approach to unraveling epigenetics. Trends Genet 2011;27:116-25.
35. Holliday R. Epigenetics: an overview. Dev Genet 1994;15:453-7.
36. Fraga MF, Ballestar E, Paz MF, et al. Epigenetic differences arise during the lifetime of monozygotic twins. Proc Natl Acad Sci USA 2005;102:10604-9.
37. Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005;438:685-9.
38. Baltimore D, Boldin MP, O'Connell RM, et al. MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008;9:839-45.
39. Loomba R, Hwang SJ, O'Donnell CJ, Sr, et al. Parental obesity and offspring serum alanine and aspartate aminotransferase levels: the Framingham heart study. Gastroenterology 2008;134:953-9.
40. Sukata T, Sumida K, Kushida M, et al. Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages. Toxicol Lett 2011;200:46-52.
41. Zhu XM, Wu LJ, Xu J, et al. Let-7c microRNA expression and clinical significance in hepatocellular carcinoma. J Int Med Res 2011;39:2323-9.
42. Hand NJ, Master ZR, Eauclaire SF, et al. The microRNA-30 family is required for vertebrate hepatobiliary development. Gastroenterology 2009;136:1081-90.
43. Zarrinpar A, Loomba R. Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2012;36:909-21.
44. Younossi ZM, Afendy A, Stepanova M, et al. Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C. Liver Int 2009;29:1403-12.
45. Wu J, Zhou Q, Wang Y, et al. MNT inhibits the migration of human hepatocellular carcinoma SMMC7721 cells. Biochem Biophys Res Commun 2012;418:93-7.
46. Fan J, Lou B, Chen W, et al. Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest. Tumour Biol 2014;35:11523-32.
47. Gui Y, Yeganeh M, Cepero-Donates Y, et al. Regulation of MET receptor signaling by SOCS1 and its implications for hepatocellular carcinoma. Curr Pharm Des 2014;20:2922-33.
48. Gui Y, Yeganeh M, Donates YC, et al. Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma. Oncogene 2015. doi: 10.1038/onc.2015.20
49. Inagaki-Ohara K, Kondo T, Ito M, et al. SOCS, inflammation, and cancer. Jak-Stat 2013;2:e24053.